Bristol-Myers Squibb Co.

BMY

Bristol-Myers Squibb Co. is a global pharmaceutical company focused on discovering, developing, and delivering innovative medicines in areas such as oncology, immunology, cardiovascular, and neuroscience. Founded in 1858, it has a long history of advancing health through its diverse portfolio of prescription therapies.

$60.74 +0.28 (0.46%)
Dividend Yield 4.13%
Payout Frequency Quarterly

Dividend History

🎉 Upcoming Dividend

Investors can expect a dividend payout of $0.63 per share, scheduled to be distributed in 16 days on August 3, 2026

Pay DateAmountEx-DateRecord Date
August 3, 2026$0.632026-07-022026-07-02
May 1, 2026$0.632026-04-022026-04-02
February 2, 2026$0.632026-01-022026-01-02
November 3, 2025$0.622025-10-032025-10-03
August 1, 2025$0.622025-07-032025-07-03

Dividends Summary

Company News

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider
GlobeNewswire Inc. • Sns Insider • July 15, 2026

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% ...

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
GlobeNewswire Inc. • Na • July 13, 2026

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the h...

2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now
The Motley Fool • Prosper Junior Bakiny • July 7, 2026

Pfizer and Bristol Myers Squibb are presented as attractively valued dividend stocks despite recent challenges. Both pharmaceutical companies face patent cliffs but have strong pipelines with promising candidates in oncology, weight loss, and anticoagulants. With forward yields of 7.1% and 4.3% respectively, and trading at discounted valuations (...

Exploring the Cancer Metabolism-Based Therapeutics Market: Key Drivers and Challenges to $26.3 Billion Growth
GlobeNewswire Inc. • Researchandmarkets.Com • July 3, 2026

The cancer metabolism-based therapeutics market is projected to grow from $3.7 billion in 2026 to $26.3 billion by 2035, driven by precision medicine approaches and rising cancer prevalence. The market includes approximately 250 therapeutic programs targeting cancer metabolism vulnerabilities, with North America expected to hold over 45% market s...

Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool • Sara Appino • June 26, 2026

The article compares two major healthcare stocks: Bristol Myers Squibb (BMY), a specialized biopharmaceutical company focused on oncology and immunology, and Johnson & Johnson (JNJ), a diversified healthcare giant with innovative medicine and medical device segments. While BMY trades at a significant valuation discount with a higher dividend yiel...

Related Companies